panobinostat + lenalidomide + bortezomib + dexamethasone

This drug is a **four-drug combination regimen** comprising panobinostat, lenalidomide, bortezomib, and dexamethasone, primarily evaluated for the treatment of **relapsed or refractory multiple myeloma**. - **Panobinostat** is a histone deacetylase (HDAC) inhibitor that induces cell cycle arrest and apoptosis by causing hyperacetylation of histone proteins and affecting gene transcription, disrupting oncogenic pathways and overcoming drug resistance. - **Lenalidomide** is an immunomodulatory agent that exerts antineoplastic effects by modulating the immune microenvironment, reducing angiogenesis, and inducing apoptosis in malignant plasma cells. - **Bortezomib** is a proteasome inhibitor that prevents the breakdown of pro-apoptotic factors, leading to cancer cell apoptosis. - **Dexamethasone** is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties, used to enhance the cytotoxic effects of anti-myeloma agents. Preclinical and early-phase clinical studies indicate that the combination has synergistic anti-myeloma effects, with panobinostat potentiating the efficacy of established regimens and overcoming resistance in heavily pre-treated and refractory patient populations[1][5][6].

Other names

panobinostat + lenalidomide + bortezomib + dexamethasonepano-RVd